News about Manel Juan
- Jan (21)
- Feb (19)
- Mar (23)
- Apr (22)
- May (22)
- Jun (20)
- Jul (27)
- Aug (10)
- Sep (24)
- Oct (24)
- Nov (34)
- Dec (20)
- Jan (24)
- Feb (27)
- Mar (15)
- Apr (23)
- May (34)
- Jun (28)
- Jul (26)
- Aug (11)
- Sep (19)
- Oct (20)
- Nov (28)
- Dec (14)
- Jan (14)
- Feb (22)
- Mar (21)
- Apr (12)
- May (20)
- Jun (23)
- Jul (20)
- Aug (5)
- Sep (19)
- Oct (19)
- Nov (26)
- Dec (15)
- Jan (4)
- Feb (18)
- Mar (13)
- Apr (15)
- May (19)
- Jun (22)
- Jul (18)
- Aug (9)
- Sep (11)
- Oct (25)
- Nov (19)
- Dec (15)
- Jan (12)
- Feb (6)
- Mar (13)
- Apr (5)
- May (7)
- Jun (15)
- Jul (11)
- Aug (3)
- Sep (5)
- Oct (8)
- Nov (15)
- Dec (13)
Hospital Clínic-IDIBAPS, pioneer in CAR T-cell therapies for cancer with over 500 patients treated
Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
Green light for ARI0002h CAR-T developed by Clínic-IDIBAPS for patients with multiple myeloma
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
IDIBAPS researchers receive two grants from the Mutua Madrileña Foundation
The selected projects were coordinated by Manel Juan, head of the Immunogenetics and Immunotherapy in Autoinflammatory and Immune Responses group and1
IDIBAPS leads an 8-million-euro immunotherapy project granted by the Spanish Association Against Cancer to improve survival in hepatocellular carcinoma
Dr. Llovet (Clínic-IDIBAPS) and Dr. Bustelo (CSIC-University of Salamanca) coordinate the ASPIRE-AECC project, which includes 15 hospitals to conduct1
Premiere of the documentary 'ARI, a story of love and life', about how the CAR-T became a reality at the Clínic
The Hospital Clínic Barcelona has presented the documentary ARI. "A story of love and lif", which tells the story of Ariana Benedé, Ari, and how a gr1
The CAR T-cell therapy from the Hospital Clínic-IDIBAPS for multiple myeloma is effective in patients with refractory disease
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
The Hospital Clínic starts an immunotherapy trial based on tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Hospital Clínic-IDIBAPS has developed a CAR-T cell therapy for multiple myeloma that shows an effectiveness of over 70% after one-year follow-up
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
Dr. Manel Juan:" “There are no good vaccines or bad vaccines”
Interview with Dr. Manel Juan, head of the Immunology Service